• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cephalon, Inc. - Product Pipeline Review - Q4 2010 - Product Image

Cephalon, Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • Region: Global
  • 129 pages
  • Global Markets Direct

Cephalon, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Cephalon, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cephalon, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cephalon, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the READ MORE >



List of Tables
List of Figures
Cephalon, Inc. Snapshot
Cephalon, Inc. Overview
Key Information
Key Facts
Cephalon, Inc. – Research and Development Overview
Key Therapeutic Areas
Cephalon, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Cephalon, Inc. – Pipeline Products Glance
Cephalon, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Cephalon, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cephalon, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Cephalon, Inc. – Drug Profiles
CEP-701
Product Description
Mechanism of Action
R&D Progress
Nuvigil
Product Description
Mechanism of Action
R&D Progress
Treanda
Product Description
Mechanism of Action
R&D Progress
Trisenox + Cytarabine
Product Description
Mechanism of Action
R&D Progress
CEP-18770
Product Description
Mechanism of Action
R&D Progress
CEP-701
Product Description
Mechanism of Action
R&D Progress
Cinquil
Product Description
Mechanism of Action
R&D Progress
Lupuzor
Product Description
Mechanism of Action
R&D Progress
Myocet + Cyclophosphamide + Trastuzumab + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Myocet + Taxoter + Herceptin
Product Description
Mechanism of Action
R&D Progress
SDX-105 + Rituxan
Product Description
Mechanism of Action
R&D Progress
Treanda + Ofatumumab
Product Description
Mechanism of Action
R&D Progress
Treanda + Velcade
Product Description
Mechanism of Action
R&D Progress
Trisenox
Product Description
Mechanism of Action
R&D Progress
cep-11981
Product Description
Mechanism of Action
R&D Progress
CEP-18770
Product Description
Mechanism of Action
R&D Progress
CEP-26401
Product Description
Mechanism of Action
R&D Progress
CEP-33222
Product Description
Mechanism of Action
R&D Progress
CEP-33236
Product Description
Mechanism of Action
R&D Progress
CEP-33237
Product Description
Mechanism of Action
R&D Progress
CEP-37251
Product Description
Mechanism of Action
R&D Progress
CEP-9722
Product Description
Mechanism of Action
R&D Progress
CEP-9722 + Temozolomide
Product Description
Mechanism of Action
R&D Progress
ART010
Product Description
Mechanism of Action
R&D Progress
ART101
Product Description
Mechanism of Action
R&D Progress
ART104
Product Description
Mechanism of Action
R&D Progress
ART150
Product Description
Mechanism of Action
R&D Progress
CEP-28122
Product Description
Mechanism of Action
R&D Progress
CEP-28331
Product Description
Mechanism of Action
R&D Progress
CEP-32496
Product Description
Mechanism of Action
R&D Progress
CEP-37250
Product Description
Mechanism of Action
R&D Progress
CEP-37251
Product Description
Mechanism of Action
R&D Progress
PMX53
Product Description
Mechanism of Action
R&D Progress
ART140
Product Description
Mechanism of Action
R&D Progress
ART160
Product Description
Mechanism of Action
R&D Progress
Cephalon, Inc. – Pipeline Analysis
Cephalon, Inc. – Pipeline Products by Therapeutic Class
Cephalon, Inc. Pipeline Products By Target
Cephalon, Inc. – Pipeline Products by Molecule Type
Cephalon, Inc. - Dormant Projects
Cephalon, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CEP-1347
CEP-701
SDX-101
Cephalon, Inc. – Company Statement
Cephalon, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 22, 2010: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy Of NUVIGIL
Oct 22, 2010: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy Of NUVIGIL
Oct 22, 2010: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy Of NUVIGIL
Oct 22, 2010: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy Of PROVIGIL
Oct 22, 2010: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy Of PROVIGIL
Oct 22, 2010: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy Of PROVIGIL
Jun 02, 2010: Cephalon Provides Clinical Update On Phase II Study Of NUVIGIL As Adjunctive Therapy In Adults With Schizophrenia
Apr 06, 2010: Cephalon Announces Positive Results From A Phase Three Study Of NUVIGIL In Jet Lag Disorder
Mar 29, 2010: Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
Mar 29, 2010: Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
Financial Deals Landscape
Cephalon, Inc., Deals Volume Summary, 2004 to YTD 2010
Cephalon, Inc., Deals Summary By Region, 2004 to YTD 2010
Cephalon, Inc., Deals Summary, 2004 to YTD 2010
Cephalon, Inc. Detailed Deal Summary
Asset Purchase
Anesta Acquires Amrix From ECR Pharmaceuticals
Acquisition
Cephalon Exercises Its Option To Acquire BioAssets Development
Cephalon Acquires Ception Therapeutics
Cephalon Acquires Arana Therapeutics
Cephalon Acquires Zeneus Holdings
Cephalon Acquires Salmedix
Venture Financing
SymBio Pharmaceuticals Secures $8 Million In Second Tranche Of Series D Financing
Equity Offering
Cephalon Completes Public Offering Of $300 Million
Thuris Completes Private Placement Of $3.8 Million
Debt Offering
Cephalon Completes Public Offering Of Convertible Senior Subordinated Notes For $500 Million
Cephalon Completes Public Offering Of 2% Convertible Senior Subordinated Notes For $920 Million
Celator Pharmaceuticals Enters Into Research Agreement With Cephalon
PsychoGenics Enters Into Drug Discovery Agreement With Cephalon
Ambit Biosciences Enters Into An Agreement With Cephalon
Perrigo Enters Into Agreement With Cephalon
Cephalon Enters Into Agreement With Takeda
Pharmacopeia Enters Into A Co-Development Agreement With Cephalon
Mylan Technologies Enters Into Strategic Agreement With Cephalon
Cephalon Enters Into Agreement With McNeil Consumer
Alkermes Enters Into Agreement With Cephalon
Lundbeck Terminates Its Agreement With Cephalon
Alkermes Terminates Co-Development Agreement With Cephalon
Cephalon Terminates Co-Promotion Agreement With Takeda Pharmaceutical
Licensing Agreements
Acusphere Amends Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With SymBio Pharmaceuticals
Cephalon Enters Into Licensing Agreement With ImmuPharma
Acusphere Enters Into Licensing Agreement With Cephalon
Acusphere Enters Into Licensing Agreement With Cephalon
Ranbaxy Laboratories Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Enters Into License Agreement With Cephalon For Modafinil
Bausch & Lomb Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Barr Laboratories
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS